Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03699891 · ClinicalTrials.gov registry record
Evaluation of the Fortilink IBF System With TETRAfuse Technology
A clinical trial, sponsored by RTI Surgical.
- Completed
- Registry status
- 119
- Enrollment target
NCT03699891: Completed study, sponsored by RTI Surgical.
NCT03699891 is a clinical trial that has completed, run by RTI Surgical. The registered enrollment target is 119 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03699891 has completed, sponsored by RTI Surgical.
- COMPLETED
- Registry status
- 119 participants
- Enrollment target
Study Summary
This is a multi-center, post-market, retrospective study to collect safety and performance data for patients implanted with the Fortilink IBF System.
Primary Outcome
Safety assessment includes evaluation of all adverse events or complications related to the procedure and post-operative adverse events.
Interventions
- DEVICE Fortilink IBF System with TETRAfuse Technology
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2018-11-06 |
| Est. Completion | 2019-01-15 |
What the finished NCT03699891 record still lists
NCT03699891 is an observational study that tracks outcomes without assigning an intervention. The registered 119 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Fortilink IBF System with TETRAfuse Technology is the first listed.
NCT03699891 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03699891 about?
NCT03699891 is a clinical study titled "Evaluation of the Fortilink IBF System With TETRAfuse Technology". This is a multi-center, post-market, retrospective study to collect safety and performance data for patients implanted with the Fortilink IBF System.
What is the current status of trial NCT03699891?
This trial is currently completed. The enrollment target is 119 participants. The study started on 2018-11-06. Estimated completion is 2019-01-15.
What interventions are being tested in trial NCT03699891?
The interventions under investigation include: Fortilink IBF System with TETRAfuse Technology (DEVICE).
Who is sponsoring clinical trial NCT03699891?
This trial is sponsored by RTI Surgical, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04870762 · 119 participants · Phase 2
Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
- NCT05559853 · 119 participants
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
- NCT06564389 · 119 participants · Phase 1
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
- NCT06742801 · 119 participants · NA
Onyx™ Liquid Embolic IDE Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI